Synthetic Pseudaminic-Acid-Based Antibacterial Vaccine Confers Effective Protection against Acinetobacter baumannii Infection

Ruohan Wei; Xuemei Yang; Han Liu; Tongyao Wei; Sheng Chen; Xuechen Li

doi:10.1021/acscentsci.1c00656

Author(s)

Ruohan Wei
Han Liu
Tongyao Wei
Xuechen Li

Related Research Unit(s)

Detail(s)

Original language	English
Pages (from-to)	1535-1542
Number of pages	8
Journal / Publication	ACS Central Science
Volume	7
Issue number	9
Online published	8 Sept 2021
Publication status	Published - 22 Sept 2021

Link(s)

DOI	DOI https://doi.org/10.1021/acscentsci.1c00656 Final Published version
	Check@CityULib
Attachment(s)	Documents 83397283.pdf Final Published version, 1.35 MB, PDF Publisher's Copyright Statement This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/
Link to Scopus	https://www.scopus.com/record/display.uri?eid=2-s2.0-85115662812&origin=recordpage
Permanent Link	https://scholars.cityu.edu.hk/en/publications/publication(c6e887d6-8e7f-492f-a557-f8893a62ec1c).html

Abstract

Acinetobacter baumannii exhibits resistance to most first-line antibiotics; thus, development of new antibacterial agents is urgently required. Pseudaminic acid exists as the surface glycan of A. baumannii. In this study, we chemically synthesized pseudaminic acid, conjugated it to carrier protein CRM197 using the OPA (ortho-phthalaldehyde) chemistry, and obtained three Pse-CRM197 conjugates with different Pse loadings. These Pse-CRM197 conjugates were found to stimulate high immune responses in mice, which protected the vaccinated mice from infections caused by Pse-producing A. baumannii. Our data indicate that chemically synthesized Pse-CRM197 conjugates can be developed into vaccines against Pse-bearing pathogens, thus offering a feasible alternative for the control of clinical infections caused by multidrug-resistant (MDR) A. baumannii, for which current treatment options are extremely limited.